Several studies have linked codeletion of chromosome arms 1p/19q in low-grade gliomas (LGG) with positive response to treatment and longer progression-free survival. Hence, predicting 1p/19q status is crucial for effective treatment planning of LGG. In this study, we predict the 1p/19q status from MR images using convolutional neural networks (CNN), which could be a non-invasive alternative to surgical biopsy and histopathological analysis. Our method consists of three main steps: image registration, tumor segmentation, and classification of 1p/19q status using CNN. We included a total of 159 LGG with 3 image slices each who had biopsy-proven 1p/19q status (57 non-deleted and 102 codeleted) and preoperative postcontrast-T1 (T1C) and T2 images. We divided our data into training, validation, and test sets. The training data was balanced for equal class probability and was then augmented with iterations of random translational shift, rotation, and horizontal and vertical flips to increase the size of the training set. We shuffled and augmented the training data to counter overfitting in each epoch. Finally, we evaluated several configurations of a multi-scale CNN architecture until training and validation accuracies became consistent. The results of the best performing configuration on the unseen test set were 93.3% (sensitivity), 82.22% (specificity), and 87.7% (accuracy). Multi-scale CNN with their self-learning capability provides promising results for predicting 1p/19q status non-invasively based on T1C and T2 images. Predicting 1p/19q status non-invasively from MR images would allow selecting effective treatment strategies for LGG patients without the need for surgical biopsy.
BackgroundSegmentation of pre-operative low-grade gliomas (LGGs) from magnetic resonance imaging is a crucial step for studying imaging biomarkers. However, segmentation of LGGs is particularly challenging because they rarely enhance after gadolinium administration. Like other gliomas, they have irregular tumor shape, heterogeneous composition, ill-defined tumor boundaries, and limited number of image types. To overcome these challenges we propose a semi-automated segmentation method that relies only on T2-weighted (T2W) and optionally post-contrast T1-weighted (T1W) images.MethodsFirst, the user draws a region-of-interest (ROI) that completely encloses the tumor and some normal tissue. Second, a normal brain atlas and post-contrast T1W images are registered to T2W images. Third, the posterior probability of each pixel/voxel belonging to normal and abnormal tissues is calculated based on information derived from the atlas and ROI. Finally, geodesic active contours use the probability map of the tumor to shrink the ROI until optimal tumor boundaries are found. This method was validated against the true segmentation (TS) of 30 LGG patients for both 2D (1 slice) and 3D. The TS was obtained from manual segmentations of three experts using the Simultaneous Truth and Performance Level Estimation (STAPLE) software. Dice and Jaccard indices and other descriptive statistics were computed for the proposed method, as well as the experts’ segmentation versus the TS. We also tested the method with the BraTS datasets, which supply expert segmentations.Results and discussionFor 2D segmentation vs. TS, the mean Dice index was 0.90 ± 0.06 (standard deviation), sensitivity was 0.92, and specificity was 0.99. For 3D segmentation vs. TS, the mean Dice index was 0.89 ± 0.06, sensitivity was 0.91, and specificity was 0.99. The automated results are comparable with the experts’ manual segmentation results.ConclusionsWe present an accurate, robust, efficient, and reproducible segmentation method for pre-operative LGGs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.